The present invention relates to an adherence monitor for a blister strip dry powder inhaler. In particular, it relates to an adherence monitor with an optical sensor with a light guide for reading a non-numerical code on the blister strip.
Dry powder inhalers (DPIs) provide an attractive method for administering medicaments, for example to treat local diseases of the airway or to deliver drugs to the bloodstream via the lungs. The medicament is commonly provided as individual doses, such as a strip having a plurality of blisters, for example as disclosed in WO13/175177. The efficacy of treatment is dependent on the patient using the inhaler as prescribed. Consequently, there is increasing interest in monitoring patient adherence, i.e. whether the patient takes the prescribed number of doses per day, e.g. once or twice daily.
DPIs typically have a dose counter, either in the form of numbers printed onto the blister strip or as a separate mechanism which counts up or down each time the inhaler is actuated. However, while this tells the patient the number of remaining doses so that they know when a new inhaler is required, it does not help the caregiver to monitor adherence, because the dose number is only seen by the patient. Therefore, monitors have been developed that provide adherence information. The monitor typically has switches or sensors (e.g. optical, or acoustic) which detect when the inhaler has been actuated, and hence counts the number of doses that have been taken. However, if an actuation is not counted correctly (for example, an aborted actuation is counted, or an actuation is not counted due to sensor error) then monitor could display the incorrect dose number.
Since adherence monitors typically contain expensive sensors, electronics etc., they are often provided as separate add-on modules which couple to the inhaler. DPIs typically contain a month's supply of medication. Thus, when the medication in the inhaler has been used up, the monitor can be detached and then re-attached to a new inhaler. For example, US2010/0192948 discloses a detachable adherence monitor for a DPI which records when the inhaler is used by optically detecting movement of its mechanical parts. Since the monitor is detachable, the patient could remove it before all of the doses in the inhaler are used up. The monitor has the disadvantage that if it is later re-attached to the same inhaler, it cannot determine how many doses have been dispensed during the period in which it was detached.
Our co-pending application, WO2021/099329 seeks to overcome these drawbacks by providing a dry powder inhaler which contains a blister pack (such as a blister strip) comprising a plurality of blisters. The blister pack has non-numerical indicia which encode a number that is associated with each dose of powdered medicament. The dose number is unique within the blister strip. The inhaler is adapted for mounting a monitor, which has optical sensor(s) that read the non-numerical indicia on the blister pack. The monitor interprets the output from the optical sensor(s) from which it determines the dose number. Thus there is no possibility of the dose number being incorrect. In other words, the monitor determines the dose number in an absolute manner by reading the dose number from the blister strip, rather than in a relative manner, such as by counting uses of the inhaler as in US2010/0192948.
The present invention relates to the design of the optical system in this type of monitor. In a first aspect, the invention provides a monitor which is attachable to a dry powder inhaler that contains a blister strip comprising a plurality of blisters, wherein a blister, or group of blisters, provides a dose of powdered medicament for inhalation, wherein the blister strip has a plurality of non-numerical indicia; wherein the monitor comprises one or more optical sensors which are configured to read the non-numerical indicia; wherein the optical sensor has a light guide with a proximal end adjacent to the sensor and a distal end remote from the sensor through which light is transmitted to and received from the blister strip, wherein the distal end is convex.
The term “light guide” means a device for directing light by means of total internal reflection from a light source to a place where the light is needed. Thus a light guide differs from a transparent window which transmits light, but does not guide or direct it by total internal reflection. The proximal end of the light guide(s) which is adjacent to the optical sensor may be wider than the distal end, and the sides of the light guide(s) may be sloped, so that the light guide may have a generally trapezoidal (in particular, isosceles trapezoidal) cross-section, apart from the convex distal end. The ratio of the width of the proximal end of the light guide(s) to the width of the distal end of the light guide may be from 4:3 to 3:1, such as from 3:2 to 5:2, preferably about 2:1.
The width of the proximal end may be from 2 to 3 mm, such as about 2.4 mm; and the width of the distal end may be from 1 to 1.5 mm, such as about 1.2 mm.
The convex distal end of the light guide may have a radius of curvature of from 2 to 5 mm, such as about 3 mm.
The light guide(s) may have a height of from 2 to 3 mm, such as about 2.5 mm. The light guide(s) may have a depth of from 1 to 3 mm, such as about 1.7 mm.
The monitor may be removably attachable to the inhaler.
The optical sensor(s) may be photomicrosensors which emit and detect light reflected from the indicia on the blister strip. The optical sensor(s) may comprise a single light source, such as an LED, and two or more photodetectors.
The optical sensor(s) may operate in the visible and/or infrared regions of the electromagnetic spectrum.
The light guide(s) may be made from a transparent plastic material, such as acrylic (also known as polymethyl methacrylate or plexiglass) or polycarbonate. The light guide(s) may be built in to the housing of the monitor (i.e. they are moulded together), in which case the light guide is preferably made from polycarbonate.
In one embodiment, the monitor has three photomicrosensors and three light guides. The light guides may be moulded as a single component.
In a second aspect, the present invention provides a kit comprising a monitor of the first aspect and a dry powder inhaler which contains a blister strip comprising a plurality of blisters, wherein the blister strip has non-numerical indicia, and wherein the inhaler has an aperture into which the light guide(s) are inserted when the monitor is mounted onto the inhaler.
In a third aspect, the present invention provides a combination comprising a monitor according to the first aspect which is mounted on a dry powder inhaler that contains a blister strip comprising a plurality of blisters, wherein the blister strip has non-numerical indicia, and wherein the light guide(s) on the monitor are inserted into an aperture on the inhaler, so that the optical sensors can read the non-numerical indicia.
The monitor may be removably mounted on the inhaler, for example it may clip onto the housing of the inhaler so that a single monitor may be used with many different inhalers. Alternatively, the monitor may be intended for use with a single inhaler only, in which case it may be permanently attached to the inhaler, e.g. by ultrasonic welding or gluing.
The non-numerical indicia may each encode an individual, unique number that is associated with a dose of powdered medicament provided by a blister, or a group of blisters. The monitor reads the indicium on the blister strip associated with the current dose. From this it determines the unique number of that dose, and consequently the number of doses that have been dispensed or remain to be dispensed.
The invention will now be further described with reference to the Figures, wherein:
In the context of dry powder inhalers, the term “adherence” is normally used to refer to whether the patient takes the prescribed number of doses per day, e.g. once or twice daily. The term “compliance” is normally used to refer to whether the patient uses their inhaler correctly, e.g. if they inhale sufficiently strongly to entrain the powder and disperse it into particles that reach the lung. Various types of sensor can be used to measure adherence and/or compliance information. In the present application, the term “monitor” refers to a module having one or more sensors that is designed to measure and capture information relating to adherence, and which may additionally measure and capture compliance information. The monitor does not perform any of the functions associated with dosing the medication, such as a piercing or opening blisters, de-agglomerating the powder or providing a breath-actuation mechanism. The inhaler therefore operates to dispense powder whether the monitor is present or not.
The inhaler 1 is constructed from two shell parts 2, 3 which are joined together to form a housing that contains a blister strip. A detachable monitor 20 is attached to one side of the inhaler. A mouthpiece cover 4 is mounted onto the housing. The cover 4 can be rotated through an angle of about 100° from the closed position (
There is also a small orifice 12 in the wall of the housing, which allows a pressure sensor 26 (shown in
The inhaler has a mechanism for indexing the blister strip and a piercer for opening the blisters. The mouthpiece 5 is formed as part of a component which is pivotally mounted to the housing and the piercer 8 is mounted on the underside of the mouthpiece. The cover (not shown in
The inhaler may be configured to index and pierce one blister on each actuation. Alternatively, it may index and pierce two (or more) blisters on each actuation, and thereby deliver two (or more) different formulations simultaneously, or a double (or multiple) amount of a single formulation. Thus a dose of medicament may be provided by a single blister, in which case an individual non-numerical indicium is associated with each blister. Alternatively, a dose may be provided by two (or more) blisters, in which case an individual non-numerical indicium is associated with each pair (or group) of blisters.
The medicament is suitable for administration by inhalation, for example for the treatment of a respiratory disease. It may include one of more of the following classes of pharmaceutically active material: anticholinergics, adenosine A2A receptor agonists, β2-agonists, calcium blockers, IL-13 inhibitors, phosphodiesterase-4-inhibitors, kinase inhibitors, steroids, CXCR2, proteins, peptides, immunoglobulins such as Anti-IG-E, nucleic acids in particular DNA and RNA, monoclonal antibodies, small molecule inhibitors and leukotriene B4 antagonists. The medicament may include excipients, such as fine particles and/or carrier particles (e.g. lactose), and/or additives (e.g. magnesium stearate, phospholipid or leucine).
Suitable β2-agonists include albuterol (salbutamol), preferably albuterol sulfate; carmoterol, preferably carmoterol hydrochloride; fenoterol; formoterol; milveterol, preferably milveterol hydrochloride; metaproterenol, preferably metaproterenol sulfate; olodaterol; procaterol; salmeterol, preferably salmeterol xinafoate; terbutaline, preferably terbutaline sulphate; vilanterol, preferably vilanterol trifenatate and indacaterol, preferably indacaterol maleate. Suitable steroids include budesonide; beclamethasone, preferably beclomethasone dipropionate; ciclesonide; fluticasone, preferably fluticasone furoate; mometasone, preferably mometasone furoate. Suitable anticholinergics include: aclidinium, preferably aclidinium bromide; glycopyrronium, preferably glycopyrronium bromide; ipratropium, preferably ipratropium bromide; oxitropium, preferably oxitropium bromide; tiotropium, preferably tiotropium bromide; umeclidinium, preferably umeclidinium bromide; Darotropium bromide; and tarafenacin.
The active material may include double or triple combinations such as salmeterol xinafoate and fluticasone propionate; budesonide and formoterol fumarate dehydrate, lycopyrrolate and indacaterol maleate; glycopyrrolate, indacaterol maleate and mometasone furoate; fluticasone furoate and vilanterol; vilanterol and umeclidinium bromide; fluticasone furoate, vilanterol and umeclidinium bromide.
The monitor may have a pressure sensor 26, which is located in a recess on the inside face. The pressure sensor abuts the orifice 12 in the housing (see
The monitor has a power source, such as a rechargeable battery. The monitor may have a motion sensor, such as an accelerometer, and means for switching on the monitor when motion is detected. The motion sensor may be configured to sense a specific gesture, such as picking up the monitor. Alternatively, a reed switch and a corresponding magnet on the mouthpiece cover, or a mechanical switch which interacts with the cover can be used to switch the monitor on. This avoids the need for the monitor to be permanently switched on, and hence conserves battery power.
The monitor has a controller and memory (e.g. a suitable microprocessor) which are configured to process and/or store information from the sensors and/or switches relating to patient's usage of the inhaler. The monitor may also include means for transmitting information from the sensors and/or switches to an external device, such as a computer or smartphone, e.g. via Bluetooth®. The information may then be displayed to the user and/or a medical professional, by means of suitable software, for example a smartphone app. The information may additionally or alternatively be stored on the monitor for subsequent interrogation, and/or transmitted to an online health platform. The monitor may also include means for receiving information from an external device.
The monitor has one or more optical sensors for reading the indicia on the blister strip by means of reflected light. It can then determine the unique identity of the particular blister in a manner that is described in detail below, so that the number of doses that have been dispensed or that remain to be dispensed can be determined directly from the blister strip. In the embodiment shown in
The sensors are separated from the blister strip by the thickness of the housings of the monitor and the inhaler, which may typically be a distance of about 2 mm. The aperture in the housing of the inhaler must be narrow in order to ensure that external objects cannot be inadvertently inserted by the user if the monitor is not present. The optical sensor emits light over a range of angles. Without a light guide, a substantial amount of the light would not enter the aperture. Instead it would be reflected back to the sensor from the housing of the inhaler. This would increase the background light and reduce the ratio of the signal (i.e. the light reflected from the blister strip) to noise (i.e. the background). The light guide counteracts this by channeling light from the optical sensor to the blister strip and back.
The three optical sensors in the monitor each read one row of the code, and there are two read events as the blister strip is indexed, one for each column. However other configurations are equally possible, such as a code with two rows and three columns and a monitor with two sensors and three read events, or a 2×2 code for a blister strip with 15 blisters.
As shown in
The sensor outputs that result from the code of
In
Alternatively, a different type of coating may be used, for example, one that is fluorescent, together with a suitable optical sensor in the monitor. Another possibility is to form the indicia by creating bumps and/or dimples in the blister strip, or to mark the strip by laser ablation. These result in different amounts of reflected light compared to unmarked parts of the blister strip.
The blister strip may additionally have printed numbers. Each individual blister is associated with one of the numbers and one of the matrix codes. However, neither the number nor the bar code is located adjacent to the blister with which it is associated. The reason for this is apparent from
The blister strip has a leading end without any blisters, and then three empty blisters 44 before the first blister X filled with medicament. This is necessary because the indexing mechanism advances the blister strip by means of a drive wheel 7 which is located downstream of the piercer 8. The first filled blister X is situated directly beneath the mouthpiece 5 and the piercer 8. The number Y associated with this blister is 60, because this is the total number of doses in the inhaler before use. However, the opening 6 through which the user reads the number of doses remaining is not located adjacent to the mouthpiece, but in the sidewall of the housing close to the drive wheel 7. Consequently, the number Y associated with blister X is actually four blisters further along the blister strip in the downstream direction. Similarly, the sensors 22 which read the indicium Z associated with blister X are located at the opposite sidewall of the housing by the aperture 11. Thus the indicium Z is actually four blisters upstream of blister X and eight blisters upstream of the number Y. Indicia associated with the empty blisters may be used for control checks during production.
As shown in
The present invention addresses the problem of reading the code when the distance and the angle between the blister strip and the sensor can vary over the lifetime of the inhaler by optimizing the shape of the light guide.
The light guide 23 channels light from the LED 24 to the blister strip 40 and back to the detector 25 as indicated by the arrows. The light travels approximately perpendicularly to the blister strip 40, thereby reducing reflections from the housing of the inhaler and the housing of the monitor. The light guide is made from a material that is transparent to IR/visible radiation, for example a transparent plastic such as polycarbonate or acrylic (also known as polymethylmethacrylate or plexiglass).
The end of the light guide that is adjacent to the optical sensor 23B (the proximal end) is wider than the end that is inserted into the aperture 23A (the distal end) in the direction parallel to the blister strip (i.e. the vertical direction in
Moreover, the light reflected from the blister strip is diffuse (i.e. it is incident onto the end of the light guide from many directions), so it cannot be focused by a lens. Consequently, a curved (e.g. lensed) end would not be expected to increase the amount of reflected light that re-enters the light guide. However, the present inventors have actually found that a light guide with a convex curved end results in an improved signal to noise ratio. Without wishing to be limited by theory, it is believed that the curved end compensates for variations in the angle of the blister strip (i.e. when the blister strip is not exactly perpendicular to the main axis of the light guide). Thus the curved end allows greater tolerance of variations in the orientation of the blister strip relative to the optical sensor that occur as the coil of the unused blister strip changes in size over the lifetime of the inhaler.
It would also be expected that a cuboidal light guide (i.e. with parallel sides) would provide the most efficient transfer of light from the LED to the blister strip and back again, because this shape has the greatest internal reflection. However, the present inventors have actually found that an improved signal-to-noise ratio is obtained with a light guide that has a trapezoidal shape. Without wishing to be limited by theory, it is believed that the tapering sides allow greater tolerance of variations in the position of the indicia on the blister strip relative to the position of the optical sensor that occur as the coil of the unused blister strip changes in size over the lifetime of the inhaler.
The radius of curvature of the distal end of the light guide is suitably from 2 to 5 mm, such as about 3 mm. The light guide suitably has a width (i.e. the size in the direction parallel to the blister strip) of from 2 to 3 mm, such as about 2.4 mm at the proximal end and from 1 to 1.5 mm, such as about 1.2 mm at the distal end. The light guide may have a depth (i.e. the size perpendicular to the blister strip) of from 1 to 3 mm, such as about 1.7 mm. The depth may be constant, or the depth (like the width) may taper from the proximal end to the distal end. The light guide may have a height (i.e. the distance from the proximal end to the distal end) of from 2 to 3 mm, such as about 2.5 mm.
The monitor shown in
Experiments were conducted to compare three different light guide designs: a rectangular cross-section, a trapezoidal cross-section with a planar end and a trapezoidal cross-section with a convex curved end. Three optical sensors and three corresponding light guides were arranged to read a 3×1 matrix code on a blister strip. The light guides were inserted into the aperture of an inhaler of the type shown in
The differences between the measured voltages for 0 and 1 were calculated for the codes which contain both 0 and 1, i.e. 010 and 101. The light guides were then ranked in order of the voltage differences, from smallest (i.e. worst signal to noise ratio) to largest (i.e. best signal to noise ratio). The order was: the rectangular cross-section, the trapezoidal cross-section with a flat end, and the trapezoidal cross-section with a curved end. Thus the trapezoidal light guide with the curved end gave the best signal to noise ratio.
Number | Date | Country | Kind |
---|---|---|---|
21174144.2 | May 2021 | EP | regional |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2022/063133 | 5/16/2022 | WO |